))
Biomarkers - Are we Close? with Dr. Clair Francomano
Manage episode 448907074 series 3499428
Content provided by Dr. Linda Bluestein and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Linda Bluestein and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of the Bendy Bodies podcast, Dr. Linda Bluestein, the Hypermobility MD, has an in-depth conversation with Dr. Clair Francomano, a leading expert on connective tissue disorders and Chair of the Medical and Scientific Advisory Board for the Ehlers-Danlos Society. Dr. Francomano shares her insights on diagnosing hypermobile Ehlers-Danlos Syndrome (hEDS) versus hypermobility spectrum disorders (HSD), the current state of genetic testing, and emerging biomarkers (are we close?) that could revolutionize hEDS diagnosis. She discusses the potential connections between EDS, mast cell activation syndrome (MCAS), and postural orthostatic tachycardia syndrome (POTS), offering advice for patients navigating this complex landscape. With updates from ongoing research, this episode is essential listening for those with EDS or related conditions.
Takeaways:
Differences Between hEDS and HSD: Dr. Francomano explains the nuanced distinctions between hypermobile EDS (hEDS) and hypermobility spectrum disorders (HSD), noting that these categories may overlap more than previously thought and might benefit from unified diagnostic criteria in the future.
Genetic Testing Red Flags: While genetic testing can be useful, Dr. Francomano highlights specific “red flags” in family history or personal health that should prompt a referral to a geneticist for further investigation.
Current Limitations of Genetic Testing for hEDS: Unlike other types of EDS, hEDS currently has no identified genetic markers, meaning diagnosis relies on clinical criteria rather than genetic testing alone.
Emerging Biomarkers Show Promise: New studies, such as those exploring fibronectin and calocrine, suggest potential biomarkers for hEDS and HSD, which could transform diagnosis and treatment in the future.
Holistic Approach to Comorbidities: Dr. Francomano discusses how hEDS often presents with comorbidities like POTS and mast cell activation syndrome, recommending a comprehensive, multidisciplinary approach to manage these interconnected symptoms effectively.
Connect with YOUR Bendy Specialist, Dr. Linda Bluestein, MD at https://www.hypermobilitymd.com/.
Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them.
Join YOUR Bendy Bodies community at https://www.bendybodiespodcast.com/.
Learn more about Human Content at http://www.human-content.com
Podcast Advertising/Business Inquiries: sales@human-content.com
YOUR bendy body is our highest priority!
Learn about Dr. Clair Francomano
Her Book: https://amzn.to/4e3eSaF
Instagram: @dr.clairfrancomano
Youtube: @DoctorClair
Keep up to date with the HypermobilityMD:
YouTube: youtube.com/@bendybodiespodcast
Twitter: twitter.com/BluesteinLinda
LinkedIn: linkedin.com/in/hypermobilitymd
Facebook: facebook.com/BendyBodiesPodcast
Blog: hypermobilitymd.com/blog
Part of the Human Content Podcast Network
Learn more about your ad choices. Visit megaphone.fm/adchoices
120 episodes
Share
